BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $16,803.60 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 660 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $16,803.60. Following the transaction, the chief financial officer now owns 120,960 shares in the company, valued at approximately $3,079,641.60. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS traded down $0.97 during midday trading on Friday, reaching $25.83. 608,317 shares of the company traded hands, compared to its average volume of 283,669. The firm has a market cap of $1.21 billion, a PE ratio of -24.37 and a beta of 2.04. The stock's 50-day simple moving average is $26.65 and its 200-day simple moving average is $25.49. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million during the quarter, compared to analysts' expectations of $21.73 million. During the same period last year, the business earned ($0.21) earnings per share. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions in the fourth quarter valued at about $26,000. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the third quarter valued at about $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioLife Solutions in the fourth quarter valued at about $31,000. Quest Partners LLC bought a new position in shares of BioLife Solutions in the third quarter valued at about $57,000. Finally, 1620 Investment Advisors Inc. raised its holdings in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BLFS. Northland Securities increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. HC Wainwright raised their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. KeyCorp raised their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, TD Cowen raised their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and an average target price of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.